Quantum Genomics Société Anonyme

ENXTPA:ALQGC Stock Report

Market Cap: €5.0m

Quantum Genomics Société Anonyme Past Earnings Performance

Past criteria checks 0/6

Quantum Genomics Société Anonyme's earnings have been declining at an average annual rate of -2.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 9.9% per year.

Key information

-2.2%

Earnings growth rate

13.3%

EPS growth rate

Biotechs Industry Growth30.8%
Revenue growth rate-9.9%
Return on equityn/a
Net Margin-49,478,810.5%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Quantum Genomics Société Anonyme makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ENXTPA:ALQGC Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-910
31 Mar 240-610
31 Dec 230-320
30 Sep 230-1120
30 Jun 230-1830
31 Mar 231-2230
31 Dec 223-2530
30 Sep 223-2220
30 Jun 225-2030
31 Mar 225-1940
31 Dec 216-1740
30 Sep 217-1850
30 Jun 218-1850
31 Mar 216-1750
31 Dec 204-1640
30 Sep 204-1440
30 Jun 200-1020
31 Mar 200-1030
31 Dec 192-1040
30 Sep 190-930
30 Jun 190-1030
31 Mar 190-1130
31 Dec 180-1220
30 Sep 180-1220
30 Jun 180-1220
31 Mar 180-1020
31 Dec 170-920
30 Sep 170-820
30 Jun 170-720
31 Mar 170-620
31 Dec 160-520
30 Sep 160-520
30 Jun 160-520
31 Mar 160-420
31 Dec 150-420
30 Sep 150-310
30 Jun 150-310
31 Mar 150-210
31 Dec 140-210
30 Sep 140-210
30 Jun 140-210
31 Mar 140-210

Quality Earnings: ALQGC is currently unprofitable.

Growing Profit Margin: ALQGC is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ALQGC is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.

Accelerating Growth: Unable to compare ALQGC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALQGC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: ALQGC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 06:30
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Quantum Genomics Société Anonyme is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Soo RomanoffEdison Investment Research
Stephanie LefebvreGilbert Dupont
Martial DescouturesInvest Securities